Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacology of DAN-222 in Metastatic Breast Cancer
NCT05261269Phase 1Completed
- Sponsor
- Dantari
- Start
- Feb 2022
- Primary completion
- Sep 2023
- Modality
- Nanoparticles, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DAN-222 in breast cancer (2 arms), sponsored by Dantari. Primary endpoints: Incidence and nature of Dose Limiting Toxicities at 3 years, Incidence, nature, and severity of adverse events at 3 years and 6 more. Started Feb 2022; status: completed.
02
Drugs
DAN-222
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05261269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05261269.